China Companion Animal Health Market Size, Share and Forecast 2019-2026

SKU: DAH5 | Last Updated On: Oct 16 2019 | No. of Pages: 178 | Available Formats

In April, 2019, Scout Bio received an USD 20 million funding from GreenSpring Associates, Frazier Healthcare Partners, Adage Capital Management and Correlation Ventures to advance its operations focused on revolutionizing pet medicine by delivering a pipeline of one-time therapeutics for major chronic pet health conditions.

Market Overview

Companion animals are domesticated or domestic-bred animals whose physical, emotional, behavioral and social needs can be readily met as companions in the home or a close daily relationship with humans. Companion animal health market mainly comprises of medicines, medicinal feed additives, and vaccines and caters to both foods producing and companion animals. 

 

China Companion Animal Health Market was worth US$ XX Million in 2019 and is expected to reach US$ XX Million by 2026, at a CAGR of XX% during the forecast period 2019-2026.

 

Market Dynamics

The primary driver of the companion animal health market in China is the willingness of owners to increase spending on their pet’s health. According to a survey, pet ownership is increasing despite the costs, found that 11% of Chinese families spend more than $1,574 annually on pet care, while about 32% spend $145-435 annually. Further, rising pet ownership has led to increased demand for veterinary care, which is again fostering the demand of more companion animal pets in China thus driving the demand for companion animal health in the country. According to China's National Bureau of Statistics, in 2017 China ranked third in the world in terms of ownership where it has 73.55 million pet owners. Out of this, 46.1% own dogs and 30.7% have cats.

Rising Chinese government initiatives to promote veterinary care products is anticipated to drive the market in the foreseeable future. For instance, initiatives such as ‘One Health Initiative’ aimed to improve animal healthcare standards, has boosted the market growth prospects in the country. Several collaborative initiatives unify clinical care, control, disease surveillance, and education and research for improving the management of epidemic diseases. For instance, in August 2018, Shandong University approved a proposal to create an Ecohealth/One Health Institute in China. This new institute will comprise Chinese and international professionals who work on varied disciplines of veterinary health and environmental health for tackling major and complex health concerns in China.

 

The high cost of animal testing is the biggest barrier to the growth of the market. Further, several restrictions and regulations on animal testing have made it expensive for several healthcare companies to set up a new advanced drugs manufacturing facility for the companion animals in China. The cost of veterinary medicines and products has also increased significantly in recent years, making the animal ownership expensive and unfeasible for the middle-class population. Also, Chinese veterinary service industry lacks standardization and is unregulated. Therefore, it results in the high price to be paid by the pet owners for wailing the veterinary services, which will further restrain the market of animal health companion market in China.

 

Market Segmentation

China Animal Health Companion Market is segmented based on the product type and animal type.

 

Based on the product type, the market is segmented as –vaccines, anti-infectives, medicinal feed additives, paraciticides, diagnostic, and others. Amongst all product categories, paraciticides accounted for the largest market share of about 28% in 2018. Demand for paraciticides is rising because of an increase in flea and tick-infested Lyme disease in dogs and cats.

 

Vaccines segment is anticipated to exhibit the next highest market share during the forecast period as they are being used to companion animals to help boost their immune system against disease-causing pathogens. Further, the increasing cases of healthcare problems in companion animals have driven the need for vaccinations against multiple diseases. Owners are increasingly concerned about the safety of their pets and now opt for preventive vaccines beforehand.

Based on the animal type, the Companion Animal Healthcare is segmented by Animals into Cats, Dogs, Equine, and Others. Dogs accounted for the largest share of the market owing to health benefits associated with the adoption of the pet and rise in demand for efficient care for dogs.  Dogs pet owners in China are 24% of the population compared to 12% of the population owns cats.

 

Geographical Share

The growing popularity of owning pets in China represents a cultural shift. China’s pet ownership is booming as 24% of the population owns dogs and 12% of the population owns cats. 

 

With urbanization and even more hectic lifestyles, the emotional demand for animal companions is growing rapidly. Companion animal, health market value, have estimated to grow during the forecast period due to rising pet populations.

 

China has the highest average number of pet ownership between 2002 and 2016 worldwide, 273,474,190 pets in total. In 2017, a 34% market share the majority of a pet in China were dogs, followed by cat with a share of 20%. The two largest cities Shanghai and Beijing of China account for much of that pet ownership, with 24% of Shanghai’s residents owning dogs and 11% owning cats. Twenty-five percent of Beijing residents own dogs, while eight percent own cats.

Pet ownership is on the rise in China, which has led to increased demand for veterinary care. Owners have become more conscious of the health and well-being of their pets. Of the roughly 1.1 million animal clinics in China, 70 % are family-run practice, and the rest are mostly small medical institutions.

 

China’s vast market and its rapid development in the economy continue to maintain a strong growth leading to continuous improvements in the companion animal healthcare market.

 

In 2018, the China Pet Products Association reported that there were 50 million registered dogs in the country, with pet ownership growing at 15 % a year. Pet markets and commercial breeding centers known as dog farms have sprung up to meet the demand.

 

Competitive Landscape

The China companion animal health market is fragmented with the presence of multiple local and international players. More than 40% of the China companion animal health market is attributed to top five players –Boehringer Ingelheim, Zoetis, Bayer Healthcare, MSD Animal Health (Merck), and Virbac.

 

Boehringer Ingelheim, one of the key player in the animal health market, is enhancing market competitiveness through innovations. For instance, in April 2019, Boehringer Ingelheim launched its the first ever registered Stem Cell-Based Veterinary Medicine Arti-Cell Forte in Europe for the reduction of mild to moderate recurrent lameness associated with non-septic joint inflammation in horses.

 

Key Takeaways:

  • Pet ownership is on the rise in China, which has led to increased demand for veterinary care. Owners have become more conscious of the health and well-being of their pets. There are approximately 1.1 million animal clinics in China, 70% are family-run practices, and the rest are mostly small medical institutions.

  • China Companion Animal Health Market was valued at US$ 837.82 million in 2018 and is expected to reach US$ XX million by 2026 and is expected to grow at a CAGR of XX% during the forecast period.

  • China companion animal health market, by Paraciticides segment, was valued at $234.59 million in 2018 and is estimated to reach $395.15 million by 2026.

  • By animal type, Dogs China Companion Animal Health market is estimated to reach US$ 549.19 million by 2026 from the initial value of US$ XX million in 2018. The market is growing at a CAGR of XX% during the forecast period (2019-2026).

  • The Chinese companion animal health market is fragmented with the presence of many local and international players. However, more than 40% of the China companion animal health market is attributed to the top five players –Boehringer Ingelheim, Zoetis, Bayer Healthcare, MSD Animal Health (Merck), and Virbac.

 

Why purchase the report?

  • Visualize the composition of the companion animal health market across each indication, in terms of type and by type highlighting the key commercial assets and players.

  • Identify commercial opportunities in companion animal health by analyzing trends and co-development deals.

  • Excel data sheets with thousands of data points of companion animal health market- level 4/5 segmentation.

  • A PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

  • Product mapping in excel for the key products of all major market players.

 

Target Audience:

  • Medical device companies

  • Hospitals and clinics

  • Research and consulting firms

  • Healthcare associations/institutes

  • Venture capitalists

  • Government agencies

  1. China Companion Animal Health Market Methodology and Scope

    1. Research Methodology

    2. Research Objective and Scope of the Report

  2. China Companion Animal Health Market – Market Definition and Overview

  3. China Companion Animal Health Market– Executive Summary

    1. Market Snippet by Product   

    2. Market Snippet by Animal

    3. DataM CLO Scenario

  4. China Companion Animal Health Market– Market Dynamics

    1. Market Impacting Factors

      1. Drivers

        1. Increasing number of companion animal ownership

        2. Advances in animal health medicines and vaccines 

      2. Restraints

        1. Increasing cost of animal testing and veterinary services

        2. Changes in distribution channel might hamper the market growth

      3. Impact Analysis

  5. China Companion Animal Health Market– Industry Analysis 

    1. Porter's Five Forces Analysis 

  6. China Companion Animal Health Market– By Product   

    1. Introduction 

      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product  

      2. Market Attractiveness Index, By Product  

    2. Vaccines

      1. Introduction

      2. Market Size Analysis, and Y-o-Y Growth Analysis (%)

    3. Anti-Infectives

    4. Medicinal Feed Additives

    5. Paraciticides

    6. Diagnostics

    7. Others

  7. China Companion Animal Health Market– By Animals

    1. Introduction 

      1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Animals

      2. Market Attractiveness Index, By Animals

    2. Cats

      1. Introduction 

      2. Market Size Analysis, and Y-o-Y Growth Analysis (%)

    3. Dogs

    4. Equine

    5. Others

  8. China Companion Animal Health Market-By Region

    1. China

      1. Introduction

      2. Key Region-Specific Dynamics

      3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Product  

      4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Animals

  9. China Companion Animal Health Market– Competitive Landscape

    1. Competitive Scenario

    2. Competitor China Companion Animal Health Market Strategy Analysis

    3. Comparative Product Portfolio Analysis

    4. Market Positioning/Share Analysis

    5. Mergers and Acquisitions Analysis

  10. China Companion Animal Health Market - Company Profiles

    1. MSD Animal Health China (Merck)

      1. Company Overview

      2. Company Portfolio and Description

      3. Key Highlights

      4. Financial Overview

    2. Ceva Santé Animale

    3. Bayer Healthcare

    4. Virbac

    5. Boehringer Ingelheim

    6. Zoetis

    7. Elanco

    8. China Animal Healthcare Ltd

    9. Ringpu

    10. Zhejiang Shenghua Biok Biology Co Ltd

  11. China Companion Animal Health Market– Premium Insights

  12. China Companion Animal Health Market– DataM 

    1. Appendix

    2. About Us and Services

    3. Contact Us

List of Tables:

TABLE 1. CHINA COMPANION ANIMAL HEALTH MARKET VALUE 2018, 2022 & 2026 (US$ MN), BY PRODUCT, ($MILLION)

TABLE 2. CHINA COMPANION ANIMAL HEALTH MARKET VALUE 2018, 2022 & 2026 (US$ MN), BY ANIMALS, ($MILLION)

TABLE 3.    CHINA COMPANION ANIMAL HEALTH MARKET SHARE 2018, 2022 & 2026 (%), BY PRODUCT TYPE ($MILLION)

TABLE 4.    CHINA COMPANION ANIMAL HEALTH MARKET VALUE (US$ MN), BY PRODUCT TYPE, 2018–2026 ($MILLION)

TABLE 05.    CHINA COMPANION ANIMAL HEALTH MARKET SHARE 2018, 2022 & 2026 (%), BY ANIMAL TYPE ($MILLION)

TABLE 06.    CHINA COMPANION ANIMAL HEALTH MARKET VALUE (US$ MN), BY ANIMAL TYPE, 2018–2026 ($MILLION)

TABLE 7.     MSD ANIMAL HEALTH CHINA (MERCK): OVERVIEW

TABLE 8.    MSD ANIMAL HEALTH CHINA (MERCK): PRODUCT PORTFOLIO

TABLE 9.    MSD ANIMAL HEALTH CHINA (MERCK): KEY DEVELOPMENTS

TABLE 10.    CEVA SANTÉ ANIMALE: OVERVIEW

TABLE 11.    CEVA SANTÉ ANIMALE: PRODUCT PORTFOLIO

TABLE 12.    CEVA SANTÉ ANIMALE: KEY DEVELOPMENTS

TABLE 13.    BAYER HEALTHCARE: OVERVIEW

TABLE 14.    BAYER HEALTHCARE: PRODUCT PORTFOLIO

TABLE 15.    BAYER HEALTHCARE: KEY DEVELOPMENTS

TABLE 16.    VIRBAC: OVERVIEW

TABLE 17.    VIRBAC: PRODUCT PORTFOLIO

TABLE 18.    VIRBAC: KEY DEVELOPMENTS

TABLE 19.    BOEHRINGER INGELHEIM: OVERVIEW

TABLE 20.    BOEHRINGER INGELHEIM: PRODUCT PORTFOLIO

TABLE 21.    BOEHRINGER INGELHEIM: KEY DEVELOPMENTS

TABLE 22.    ZOETIS: OVERVIEW

TABLE 23.    ZOETIS: PRODUCT PORTFOLIO

TABLE 24.    ZOETIS: KEY DEVELOPMENTS

TABLE 25.    ELANCO: OVERVIEW

TABLE 26.    ELANCO: PRODUCT PORTFOLIO

TABLE 27.    ELANCO: KEY DEVELOPMENTS

TABLE 28.    CHINA ANIMAL HEALTHCARE LTD: OVERVIEW

TABLE 29.    CHINA ANIMAL HEALTHCARE LTD: PRODUCT PORTFOLIO

TABLE 30.    CHINA ANIMAL HEALTHCARE LTD: KEY DEVELOPMENTS

TABLE 31.    RINGPU: OVERVIEW

TABLE 32.    RINGPU: PRODUCT PORTFOLIO

TABLE 33.    RINGPU: KEY DEVELOPMENTS

TABLE 34.    ZHEJIANG SHENGHUA BIOK BIOLOGY CO LTD.: OVERVIEW

TABLE 35.    ZHEJIANG SHENGHUA BIOK BIOLOGY CO LTD.: PRODUCT    PORTFOLIO

TABLE 36.    ZHEJIANG SHENGHUA BIOK BIOLOGY CO LTD.: KEY DEVELOPMENTS

 

LIST OF FIGURES

FIGURE 01.    CHINA COMPANION ANIMAL HEALTH MARKET SHARE, 2019 & 2026 (%), BY PRODUCT   

FIGURE 02.    CHINA COMPANION ANIMAL HEALTH MARKET   SHARE, 2019 & 2026 (%), BY ANIMAL  

FIGURE 03.    CHINA COMPANION ANIMAL HEALTH MARKET VALUE, 2018 - 2026 (US$ MN) AND YEAR ON YEAR GROWTH

FIGURE 4.    CHINA COMPANION ANIMAL HEALTH MARKET YEAR ON YEAR GROWTH 2019 TO 2026 (%), BY PRODUCT TYPE   

FIGURE 5.     CHINA COMPANION ANIMAL HEALTH MARKET VALUE (US$ MN), VACCINES, 2019–2026 ($MILLION)

FIGURE 6.     CHINA COMPANION ANIMAL HEALTH MARKET VALUE (US$ MN), ANTI-INFECTIVES, 2019–2026 ($MILLION)

FIGURE 7.     CHINA COMPANION ANIMAL HEALTH MARKET VALUE (US$ MN), MEDICINAL FEED ADDITIVES, 2019–2026 ($MILLION)

FIGURE 8.     CHINA COMPANION ANIMAL HEALTH MARKET VALUE (US$ MN), PARACITICIDES, 2019–2026 ($MILLION)

FIGURE 9.     CHINA COMPANION ANIMAL HEALTH MARKET VALUE (US$ MN), DIAGNOSTICS, 2019–2026 ($MILLION)

FIGURE 10.     CHINA COMPANION ANIMAL HEALTH MARKET VALUE (US$ MN), OTHERS, 2019–2026 ($MILLION)

FIGURE 11.   CHINA COMPANION ANIMAL HEALTH MARKET YEAR ON YEAR GROWTH 2019 TO 2026 (%), BY ANIMALS   

FIGURE 12.     CHINA COMPANION ANIMAL HEALTH MARKET VALUE (US$ MN), DOGS, 2019–2026 ($MILLION)

FIGURE 13.     CHINA COMPANION ANIMAL HEALTH MARKET VALUE (US$ MN), CATS, 2019–2026 ($MILLION)

FIGURE 14.     CHINA COMPANION ANIMAL HEALTH MARKET VALUE (US$ MN), EQUINE, 2019–2026 ($MILLION)

FIGURE 15.     CHINA COMPANION ANIMAL HEALTH MARKET VALUE (US$ MN), OTHERS, 2019–2026 ($MILLION)

FIGURE 16.    CHINA COMPANION ANIMAL HEALTH MARKET YEAR ON YEAR GROWTH 2019 TO 2026 (%), BY CHINA

FIGURE 17.     MSD ANIMAL HEALTH CHINA (MERCK): FINANCIALS

FIGURE 18.    CEVA SANTÉ ANIMALE.: FINANCIALS

FIGURE 19.    BAYER HEALTHCARE: FINANCIALS

FIGURE 20.    VIRBAC: FINANCIALS

FIGURE 21.    BOEHRINGER INGELHEIM: FINANCIALS

FIGURE 22.    ZOETIS: FINANCIALS

FIGURE 23.     ELANCO: FINANCIALS

FIGURE 24.    CHINA ANIMAL HEALTHCARE LTD: FINANCIALS

FIGURE 25.    RINGPU: FINANCIALS

FIGURE 26.    ZHEJIANG SHENGHUA BIOK BIOLOGY CO LTD.: FINANCIALS

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
step 1We collate your requirements.
step 2Our global research team is put into action.
step 3We deliver, and make sure your endeavour is a success!

Buy This Report